KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

CRISPR Therapeutics AG (CRSP) EBIT Margin: 2015-2025

Historic EBIT Margin for CRISPR Therapeutics AG (CRSP) over the last 10 years, with Sep 2025 value amounting to -14,854.78%.

  • CRISPR Therapeutics AG's EBIT Margin rose 343924.00% to -14,854.78% in Q3 2025 from the same period last year, while for Sep 2025 it was -1,498.28%, marking a year-over-year decrease of 133440.00%. This contributed to the annual value of -1,250.38% for FY2024, which is 119043.00% down from last year.
  • As of Q3 2025, CRISPR Therapeutics AG's EBIT Margin stood at -14,854.78%, which was up 42.22% from -25,708.97% recorded in Q2 2025.
  • Over the past 5 years, CRISPR Therapeutics AG's EBIT Margin peaked at 84.67% during Q2 2021, and registered a low of -2,192,350.00% during Q4 2022.
  • Moreover, its 3-year median value for EBIT Margin was -16,006.81% (2025), whereas its average is -13,351.50%.
  • Per our database at Business Quant, CRISPR Therapeutics AG's EBIT Margin plummeted by 219,122,047bps in 2022 and then skyrocketed by 219,238,458bps in 2023.
  • CRISPR Therapeutics AG's EBIT Margin (Quarterly) stood at -1,129.53% in 2021, then crashed by 219,122,047bps to -2,192,350.00% in 2022, then surged by 219,238,458bps to 34.58% in 2023, then plummeted by 21,555bps to -180.96% in 2024, then surged by 343,924bps to -14,854.78% in 2025.
  • Its EBIT Margin stands at -14,854.78% for Q3 2025, versus -25,708.97% for Q2 2025 and -17,158.84% for Q1 2025.